Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.29 HKD
Change Today -0.31 / -6.74%
Volume 652.0K
1061 On Other Exchanges
Symbol
Exchange
1061 is not on other exchanges.
As of 4:01 AM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

essex bio-technology ltd (1061) Snapshot

Open
$4.36
Previous Close
$4.60
Day High
$4.43
Day Low
$4.25
52 Week High
04/13/15 - $5.72
52 Week Low
07/14/14 - $2.47
Market Cap
2.4B
Average Volume 10 Days
521.4K
EPS TTM
$0.05
Shares Outstanding
556.8M
EX-Date
05/13/15
P/E TM
78.4x
Dividend
$0.02
Dividend Yield
0.51%
Current Stock Chart for ESSEX BIO-TECHNOLOGY LTD (1061)

Related News

No related news articles were found.

essex bio-technology ltd (1061) Related Businessweek News

No Related Businessweek News Found

essex bio-technology ltd (1061) Details

Essex Bio-Technology Limited, an investment holding company, develops, manufactures, and sells biopharmaceutical products for the treatment and healing of surface wounds and eye wounds in the People’s Republic of China. The company is also involved in the research and development of basic fibroblast growth factor products for new indications, as well as other ophthalmic pharmaceutical projects; and marketing and distribution of biopharmaceutical products. Its products include Beifushu eye drops and eye gel that enhances corneal reparation and corneal wound healing; and Beifuji spray, Beifuji Lyophilized powder, and Beifuxin gel to treat burn and scald wounds, acute wounds, surgical incisions, chronic wounds, and skin grafting, as well as for use in other applications. The company’s products also comprise Diclofenac Sodium eye drops for treating uveitis keratitis and scleritis, and controlling corneal neovascularization; inflammation caused by ocular operation, laser trabeculoplasty, and various ocular injuries; pain and inflammation after photorefractive keratectomy; and allergic ocular diseases, such as spring conjunctivitis and seasonal allergic conjunctivitis, as well as for pupillary responses during cataract surgery. Its Diclofenac Sodium eye drops are also used in treating and preventing inflammation after cataract surgery and intraocular lens procedures, as well as cystoid macular edema; and for accelerating the formation of filtering bleb after glaucoma filtering surgery. The company was incorporated in 2000 and is headquartered in Zhuhai, the People’s Republic of China.

695 Employees
Last Reported Date: 03/23/15
Founded in 2000

essex bio-technology ltd (1061) Top Compensated Officers

Managing Director, General Manager and Execut...
Total Annual Compensation: $1.3M
Founder, Chairman, Member of Nomination Commi...
Total Annual Compensation: $1.5M
Compliance Officer, Executive Director and Me...
Total Annual Compensation: $1.1M
Compensation as of Fiscal Year 2014.

essex bio-technology ltd (1061) Key Developments

Essex Bio-Technology Ltd. Approves Final Dividend for the Year Ended 31 December 2014

Essex Bio-Technology Ltd. approved a final dividend of HKD 0.022 per share for the year ended 31 December 2014 at the AGM held on 8 May 2015.

Essex Bio-Technology Ltd. Presents at Macquarie Greater China Conference, May-04-2015

Essex Bio-Technology Ltd. Presents at Macquarie Greater China Conference, May-04-2015 . Venue: Conrad Hong Kong Hotel, Hong Kong, Hong Kong. Speakers: Haizhou Fang, Managing Director, General Manager and Executive Director, Mei Han, Investor Relations.

Essex Bio-Technology Ltd., Annual General Meeting, May 08, 2015

Essex Bio-Technology Ltd., Annual General Meeting, May 08, 2015., at 14:00 China Standard Time. Location: Kennedy Room, Level 7, Conrad Hong Kong. Agenda: To consider the audited consolidated financial statements and the reports of the directors and auditors of the company for the year ended 31 December 2014; to re-elect the retiring directors and to authorise the board of directors to fix the remuneration of the directors of the company; to re-appoint BDO Limited as the auditors of the company and to authorise the board of directors to fix their remuneration; to consider and declare a final dividend of HKD 0.022 per share for the year ended 31 December 2014; and to consider exercise by the directors of the powers of the company to allot, issue or otherwise deal with unissued shares in the capital of the company and to make or grant offers, agreements, options and other rights.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
1061:HK $4.29 HKD -0.31

1061 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 1061.
View Industry Companies
 

Industry Analysis

1061

Industry Average

Valuation 1061 Industry Range
Price/Earnings 31.9x
Price/Sales 4.6x
Price/Book 7.2x
Price/Cash Flow 31.7x
TEV/Sales 4.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ESSEX BIO-TECHNOLOGY LTD, please visit www.essexbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.